3rd European Conference on Schizophrenia Research – Facts and Visions

Joint thematic congress of the Competence Network on Schizophrenia, the German Association for Psychiatry and Psychotherapy, and the European Psychiatric Association

29 September – 1 October 2011
Berlin, Germany

in cooperation with

WPA World Psychiatric Association
and its Section on Schizophrenia

ASIAN NETWORK FOR SCHIZOPHRENIA RESEARCH

Final Programme

accredited by the European Council for Continuing Education (EACCME) with 15 CME credits

www.schizophrenianet.eu
# TABLE OF CONTENT

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Address</td>
<td>3</td>
</tr>
<tr>
<td>Conference Organisation</td>
<td>4</td>
</tr>
<tr>
<td>Conference Information</td>
<td>5</td>
</tr>
<tr>
<td>Format Descriptions /CME Credits</td>
<td>8</td>
</tr>
<tr>
<td>Opening Ceremony and Welcome Reception</td>
<td>10</td>
</tr>
<tr>
<td>Overview Scientific Programme</td>
<td>11</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td></td>
</tr>
<tr>
<td>Thursday, 29 September</td>
<td>14</td>
</tr>
<tr>
<td>Friday, 30 September</td>
<td>24</td>
</tr>
<tr>
<td>Saturday, 1 October</td>
<td>38</td>
</tr>
<tr>
<td>Acknowledgements</td>
<td>50</td>
</tr>
<tr>
<td>Floorplan</td>
<td>50</td>
</tr>
<tr>
<td>Index Chairpersons, Authors and Presenters</td>
<td>52</td>
</tr>
</tbody>
</table>
Dear Colleagues,

Schizophrenia is a very complex disorder and even now, 100 years after it was first described, we know very little about its causes and origins. The available treatments often do not adequately meet the heterogeneous needs of schizophrenia patients. In recent years, controversies about the aetiology of schizophrenia, the significance of the symptomatology, reliable diagnosis and appropriate classification systems and, of course, optimal and personalized treatment have initiated much research in this field and created a vast amount of data. The development of new technologies has provided new insights into some of the pathogenetic pathways of the disorder.

For the above reasons, it is vital to critically discuss recent advances and to regularly update the scientific knowledge about schizophrenia and translate it into clinical practice. The identification of emerging issues for schizophrenia research and, as a consequence, the outlining of a research agenda and initiation of respective collaborations and networking activities are forward-looking tasks for the scientific community. In addition, it is necessary to promote the implementation of evidence-based strategies to meet challenges such as treatment non-adherence, stigma and social exclusion as well as to ensure the quality of care.

The Competence Network on Schizophrenia initiated and has meanwhile established the European Conference on Schizophrenia Research (ECSR) as a forum to promote these comprehensive and significant issues. Accordingly, the scientific programme of this year’s 3rd ECSR includes high quality contributions from acknowledged experts, young scientists, and clinicians, all of whom have the common goal of improving the situation of patients. A broad range of topics will be presented in plenary lectures, prearranged and submitted symposia, workshops, and oral presentation and poster sessions. As in previous years, the co-organising psychiatric associations and their respective schizophrenia sections play a valuable role in this joint thematic conference. We are delighted that the Asian Network for Schizophrenia Research has now also become one of our partners.

On behalf of the scientific committee and the organisers, I cordially welcome you to this biennial European Schizophrenia Research Conference.

Sincerely yours,

Wolfgang Gaebel  
*Congress President and*  
*Speaker of the Competence Network on Schizophrenia*
CONFERENCE ORGANISATION

ORGANISERS

Competence Network on Schizophrenia (CNS)

European Psychiatric Association (EPA)

German Association for Psychiatry and Psychotherapy (DGPPN)

in cooperation with

WPA World Psychiatric Association and its Section on Schizophrenia

ASIAN NETWORK FOR SCHIZOPHRENIA RESEARCH

LOCAL ORGANISER

PsychoseNetz e.V.
Wolfgang Gaebel, Wolfgang Wölwer, Viktoria Toeller
c/o Department of Psychiatry and Psychotherapy
Heinrich-Heine-University Düsseldorf
LVR Clinic Center
Bergische Landstraße 2
40629 Düsseldorf, Germany

PROFESSIONAL CONFERENCE ORGANISER

Hanser & Co GmbH
Postfach 12 21
22882 Barsbüttel, Germany
Phone: +49 – 40 – 670 88 20
Fax: +49 – 40 – 670 32 83
Email: schizophrenia@cpo-hanser.de

SCIENTIFIC PROGRAMME COMMITTEE

Wolfgang Gaebel, Germany
Congress President

George Awad, Canada
Finn Bengtsson, Sweden
Dinesh Bhugra, UK
Gerd Buchkremer, Germany
George Christodoulou, Greece
Peter Falkai, Germany
Silvana Galderisi, Italy
Wagner F. Gattaz, Brazil
Birte Glenthøj, Denmark
Philippe Gorwood, France
Heinz Häfner, Germany
Cyril Höschl, Czech Republic
Joachim Klosterkötter, Germany
Valery Krasnov, Russia
Shôn Lewis, UK
Jan Libiger, Czech Republic
Wolfgang Maier, Germany
Mario Maj, Italy
Stephen Marder, USA
Patrick McGorry, Australia
Hans-Jürgen Möller, Germany
Merete Nordentoft, Denmark
Michael Owen, UK
Victor Peralta, Spain
Wulf Rössler, Switzerland
Pedro Ruiz, USA
Bernard Sabbe, Belgium
Norman Sartorius, Switzerland
Frank Schneider, Germany
Wolfgang Wölwer, Germany
Til Wykes, UK
CONFERENCE INFORMATION

CONFERENCE VENUE
The Dahlem Cube
Seminaris Science & Conference Center
Takustraße 39
14195 Berlin, Germany

CONFERENCE REGISTRATION COUNTER
All conference material and documentation are available at the conference registration counter located in the foyer on the ground floor of the Dahlem Cube.

OPENING HOURS
Thursday, 29 Sept. 2011 08.00 – 18.00 h
Friday, 30 Sept. 2011 08.00 – 18.30 h
Saturday, 1 Oct. 2011 08.00 – 16.00 h

During these opening hours the conference counter can be reached at:
Phone: +49 – 30 – 55 77 97 480

REGISTRATION FEE
On-site Registration
Competence Network members and members of
CNS, EPA, DGPPN, WPA  EUR 440,00
Non-members  EUR 490,00
Trainees *  EUR 390,00

* Non-tenured junior scientists or clinical residents in training under 35 years (Trainee status must be confirmed by a certificate in writing by head of department and copy of passport).

ON-SITE REGISTRATION
On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of conference documentation may be limited.

NAME BADGES
Participants are kindly requested to wear their name badge at all times during the conference including the Opening Ceremony and Welcome Reception.

CONFERENCE LANGUAGE
The conference language is English. Simultaneous translation will not be provided.

PROGRAMME CHANGES
The organisers cannot assume liability for any changes in the conference programme due to external or unforeseen circumstances.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be handed out upon demand at the registration counter.

ABSTRACT BOOK
All accepted abstracts are published in an abstract book as a supplement of the European Archives of Psychiatry and Clinical Neurosciences (EAPCN). The abstract book will be handed out together with the conference documentation at the registration counter.

MEDIA CHECK
The Media Check is located in room Yale 1 on the first floor of the Seminaris Science & Conference Center. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession) preferably one day before their session but at the latest 90 minutes prior to the presentation. The presentation will be transferred to a special conference notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook.

OPENING HOURS
Thursday, 29 Sept. 2011 08.00 – 18.00 h
Friday, 30 Sept. 2011 08.00 – 18.30 h
Saturday, 1 Oct. 2011 08.00 – 15.00 h
CONFERENCE INFORMATION

POSTER EXHIBITION
The poster exhibition is located in the foyer on the ground floor of the Dahlem Cube. Posters will be changed daily and are on display for the entire day of the according poster tour. They will be sorted by topics and will be numbered within those topics. The poster exhibition is open to all registered delegates:

Poster Exhibition Times for P-01 to P-03
Thursday, 29 Sept. 2011: 10.00 – 18.00 h
Guided Poster Tour: 13.30 – 14.30 h

Poster Exhibition Times for P-04 to P-07
Friday, 30 Sept. 2011: 09.00 – 18.00 h
Guided Poster Tour: 13.30 – 14.30 h

Poster Exhibition Times for P-08 to P-11
Saturday, 1 Oct. 2011: 09.00 – 16.00 h
Guided Poster Tour: 13.30 – 14.30 h

Interested participants can meet the authors for discussions of their poster presentation during the time of the poster tour.

Set-up and dismantling times for posters
Posters need to be set up and dismantled on the day of the respective poster tour within the following times:

Set-up:
Thursday, 29 Sept. 2011: 08.00 – 10.00 h
Friday, 30 Sept. 2011: 08.00 – 09.00 h
Saturday, 1 Oct. 2011: 08.00 – 09.00 h

Dismantling
Thursday, 29 Sept. 2011 and Friday, 30 Sept. 2011: 18.00 – 19.00 h
Saturday, 1 Oct. 2011: 16.00 – 17.00 h

on the day of the presentation

Posters which have not been removed within the indicated dismantling time will be disposed.

COFFEE BREAKS
Coffee, tea and mineral water will be served free of charge to all registered delegates during the morning and afternoon coffee breaks from Thursday, 29 September to Saturday, 1 October 2011. Coffee bar stations are located on the first floor and in the foyer of the ground floor next to the poster exhibition.

LUNCH AND RESTAURANTS
A lunch snack will be served to all registered delegates during the lunch breaks from Thursday, 29 September to Saturday, 1 October 2011 in the foyer of the ground floor next to the poster exhibition. The conference venue further provides a restaurant where lunch is available on cash basis.

MOBILE PHONES
Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

INSURANCE
The conference fee does not include insurance. All participants are advised to arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of residence.
How to get to the Seminaris Campus Hotel:

**From the South:** via A 103 / AS 5 Schlossstraße to the B1, Unter den Eichen, turn right into Fabeckstraße then Lansstraße

**From the East:** via A 12 / A 10 / A 113 direction airport BBI (Schönefeld / A 100 / A 103 / exit 5 Wolfensteindamm, turn right into Schlossstraße direction Dahlem / left into Grunewaldstraße / Königin-Louise-Straße / Lansstraße

**Distance to the airport:**
- **Berlin Tegel:** Transfer time by taxi approximately 30 minutes depending on traffic
- **Berlin Schönefeld:** Transfer time by taxi approximately 45 minutes depending on traffic

**By train:**
Berlin main station (ICE, IC-, RE- und RB-Station), then take the underground U3 to station “Dahlem-Dorf”. Exit the station towards Königin-Louise-Straße. Follow the road for 300 m until you reach the crossroad Takustraße.

**City hotels Kurfürstendamm:**
Point of departure: Heidelberger Platz
Take the underground U3 to Krumme Lanke and get off at Dahlem-Dorf towards direction Königin-Louise-Straße. From here 300 m walk to the Seminaris Campus Hotel.

**PARKING**
There is an underground car park with direct access to the Seminaris Campus Hotel. The parking fee is 2 Euros per hour and 12 Euros per night.
The scientific programme will comprise the following formats:

**PLENARY LECTURES**
Invited lectures of 45 min each, covering current hot spots in schizophrenia research and given by leading European experts.

**SYMPOSIA**
Pre-arranged or submitted symposia of 90 min each, including four presentations and time for discussion covering major topics of the conference. Both symposia with a clear scientific focus and those with a clear clinical focus will be included.

**WORKSHOPS**
Pre-arranged workshops allowing for detailed discussion on scientific topics in particular serving transnational collaboration within Europe. Participation included in the registration fee.

**ORAL PRESENTATION SESSIONS**
Submitted presentations grouped by topics into thematic oral sessions of 90 min, including six papers each.

**POSTER SESSIONS**
Submitted presentations grouped by topics into thematic guided poster sessions.

---

**CME ACCREDITATION**
The Competence Network on Schizophrenia c/o LVR Clinic Center, Department of Psychiatry and Psychotherapy, Düsseldorf University is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.

The 3rd European Conference on Schizophrenia Research – Facts and Visions is designated for a maximum of (or ‘for up to’) **15 hours = 15 CME credit points** of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

The EACCME is an institution of the European Union of Medical Specialists (UEMS), [www.uems.net](http://www.uems.net).

EACCME credits are recognized by the German Chamber of Physicians as well as the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit contact your regional chamber of physicians or with respect to AMA PRA category 1 credit, contact the AMA.
Sachs, Volz (Hrsg.)
**Neurokognition und Affektregulierung bei schizophrenen Psychosen**
Neuropsychologie, Bildgebung, Testdiagnostik und Behandlung

- **Praxisorientiert:** Darstellung kognitiver Defizite und diagnostischer Instrumente
- **Einblicke:** Funktionsweise betroffener Hirnareale anhand neurobiologischer Grundlagen und bildgebender Verfahren verständlich gemacht
- **Umfassend:** Integrierte Therapiekonzepte mit kognitiver Remediation, psychologischer Behandlung und atypischen Antipsychotika sowie mit neu entwickelten Medikamenten

2012. Ca. 170 Seiten, ca. 50 Abb., kart.
Ca. € 49,– (D) / € 50,40 (A)
ISBN 978-3-7945-2783-0

Häfner, Bechdolf, Klosterkötter, Maurer
**Psychosen – Früherkennung und Frühintervention**
Der Praxisleitfaden

- **Einzahl:** Erstveröffentlichung deutschsprachiger Materialien zur Abschätzung des individuellen Psychose-Risikos (ERIraos: Mannheimer Früherkennungsinventar)
- **An der Praxis ausge richtet:** Checklisten zur Früherkennung, detailliertes Interviewheft zur Gesprächsführung, Fallberichte
- **Inklusiver Online-Zugang:** Umfangreiches Zusatzmaterial exklusiv im Netz abrufbar

Ca. € 24,95 (D) / € 25,70 (A)
ISBN 978-3-7945-2704-5

Freimüller, Wölwer
**Antistigma-Kompetenz in der psychiatrisch-psychotherapeutischen und psychosozialen Praxis**

Das Trainingsmanual
- **Mit Manual für die Gruppenleitung:** Inklusive umfangreicher praxisorientierter Zusatzmaterialien
- **Mit Online-Zugang:** Zahlreiche Arbeitsmaterialien exklusiv im Netz abrufbar
- **Gemeinsam gegen Diskriminierung:** Entstanden in Zusammenarbeit mit Betroffenen

Ca. € 24,95 (D) / € 25,70 (A)
ISBN 978-3-7945-2861-5

www.schattauer.de
### Opening Ceremony

09.30 – 10.15 h  
**Plenary Room**

- **Presidential Address**  
  Professor Wolfgang Gaebel, Düsseldorf, Germany  
  *Congress President, Speaker of the Competence Network on Schizophrenia (CNS)*

- **Welcome Addresses**  
  Professor Patrice Boyer, Paris, France  
  *President of the European Psychiatric Association (EPA)*

  Professor Peter Falkai, Göttingen, Germany  
  *President of the German Association for Psychiatry and Psychotherapy (DGPPN)*

- **Award Ceremony of the Aretaeus-Award Winner 2011**

### Welcome Reception

18.00 – 19.00 h  
**Foyer**

At the end of the scientific sessions participants are invited to join the Welcome Reception in the Foyer of the Dahlem Cube. Finger food and drinks will be provided.
OVERVIEW – Thursday, 29 September 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Plenary</th>
<th>Harvard</th>
<th>Stanford</th>
<th>Princeton</th>
<th>Yale 2</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.30 - 10.15</td>
<td>5e50</td>
<td>Opening Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.15 - 11.00</td>
<td>5e50</td>
<td>PL-01 A hundred years of schizophrenia: from Bleuler to DSM-V/ICD-11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30 - 13.00</td>
<td>5e50</td>
<td>S-01 Developments in DSM-V and ICD-11 with respect to schizophrenia</td>
<td>S-02 Suicide and suicidal behavior in recent onset psychotic disorders</td>
<td>S-03 Brain imaging in the early stages of schizophrenia</td>
<td>S-04 Advances in animal models of schizophrenia: genes, environment, and prevention to biological foundations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch Break</td>
<td>13.30 – 14.30 h Guided Poster Sessions P-01 to P-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 - 14.30</td>
<td>5e50</td>
<td>S-05 The future of psychiatric genetics beyond GWAS</td>
<td>S-06 Efficacy and mechanisms of cognitive behavior therapy for psychosis results of the POSITIVE network</td>
<td>S-07 Insight in psychosis: cognitive and neural basis, and implications for treatment</td>
<td>S-08 Neuroprotective strategies in schizophrenia</td>
<td>W-01 MedicaWiki: a webbased independent evidence based psychopharmacological prescription decision system</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 - 16.00</td>
<td>5e50</td>
<td>S-09 Novel therapeutic targets for treating schizophrenia</td>
<td>S-10 Cognitive behaviour therapy for psychosis: what do we know about its effectiveness and neural correlates?</td>
<td>O-01 Co-morbidity</td>
<td>S-11 Motor symptoms as an intrinsic component of schizophrenia pathobiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lunch Break</td>
<td>18.00 – 19.00 h Welcome Reception in the Foyer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations

PL – Plenary Lecture
S – Symposium
W – Workshop
O – Oral Presentation
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Plenary</th>
<th>Harvard</th>
<th>Stanford</th>
<th>Princeton</th>
<th>Yale 2</th>
<th>Foyer</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 – 10.00</td>
<td>S-12</td>
<td>Negative symptoms of schizophrenia: assessment, domains and relationships with outcome</td>
<td></td>
<td>S-13</td>
<td>Antipsychotics in the elderly</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-14</td>
<td>Glutamate dysfunction in schizophrenia and bipolar disorder: evidence from genetics and brain imaging</td>
<td></td>
<td></td>
<td>O–02</td>
<td>Epidemiology and clinical phenotypes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td>S-15</td>
<td>Cognition in schizophrenia: from neural mechanisms to psychological interventions</td>
<td>S-16</td>
<td>EPA position statements concerning schizophrenia and beyond</td>
<td>S-17</td>
<td>Social cognition and violent behavior in schizophrenia</td>
<td>O–03</td>
</tr>
<tr>
<td>12.15 – 13.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30 – 14.30 h</td>
<td>Guided Poster Sessions P-04 to P-07</td>
<td>P-04: Epidemiology, diagnosis</td>
<td>P-05: Genetics, neurotransmission</td>
<td>P-06: Neurobiology</td>
<td>P-07: Drug treatment II: Basic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 – 16.00</td>
<td>W-02</td>
<td>Past, current and future European schizophrenia research projects</td>
<td>O-04</td>
<td>Drug and other somatic treatments</td>
<td>S-18</td>
<td>Schizophrenia – a mild encephalitis?</td>
<td>S-19</td>
</tr>
<tr>
<td></td>
<td>W-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30 – 18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td>S-20</td>
<td>Toxicity of relapse</td>
<td>S-21</td>
<td>Co-morbidity of schizophrenia and physical illness</td>
<td>S-22</td>
<td>Advances in understanding the causes of schizophrenia</td>
<td>S-23</td>
</tr>
<tr>
<td>18.15 – 19.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-24</td>
<td>Strength based treatment in an early psychosis ACT team: engaging the troublesome avoiders</td>
<td>S-25</td>
<td>Psychotic symptoms in schizophrenia – biological correlates, clinical outcome and therapeutic consequences</td>
<td>O-05</td>
<td>Psychosocial treatment</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Room</td>
<td>Plenary</td>
<td>Harvard</td>
<td>Stanford</td>
<td>Princeton</td>
<td>Foyer</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------</td>
<td>-------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>08.30 – 10.00</td>
<td>S-26</td>
<td>Psychosis: psychological therapies and their mechanisms of action</td>
<td>S-27 First-episode programmes: concepts and proven evidence</td>
<td>S-28 Dopaminergic and glutamatergic dysfunction in schizophrenia</td>
<td>O-06 Genetics and neurobiology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30 – 12.00</td>
<td>W-04</td>
<td>European practice guidelines: a need for harmonisation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12.15 – 13.00</td>
<td>PL-03</td>
<td>Social cognition and schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 – 14.30</td>
<td>S-32</td>
<td>Classification of different long-term outcomes of psychosis in schizophrenia spectrum – a need for re-conceptualization</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 – 16.00</td>
<td>S-33</td>
<td>Molecular linkage between energy metabolism and oligodendrocyte pathology in schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>S-34</td>
<td>Heterogeneity and functional significance of white matter changes in schizophrenia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>O-07</td>
<td>Neuropsychology and neuroimaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Coffee Break

Lunch Break

13.30 – 14.30 h ➤ Guided Poster Sessions P-08 to P-11

P-08: Outcome | P-09: Neuropsychology I: Basic
P-10: Neuropsychology II: Clinical | P-11: Psychosocial treatment

Registration Counter
Opening Hours: 08.00 – 16.00
PL-01
PLENARY LECTURES
10.15 – 11.00 h Plenary Room
A hundred years of schizophrenia: from Bleuler to DSM-V / ICD-11
Chair: P. Falkai, Göttingen, Germany

S-01
SYMPOSIA
11.30 – 13.00 h Plenary Room
Developments in DSM-V and ICD-11 with respect to schizophrenia
Jointly organised by the Competence Network on Schizophrenia (CNS) and the Section on Schizophrenia of the World Psychiatric Association (WPA)
Chairs: W. Gaebel, Düsseldorf, Germany
R. Tandon, Gainesville, USA

S-01-001
Trends, perspectives and problems of classification systems
N. Sartorius, Geneva, Switzerland

S-01-002
Defining schizophrenia: from Kraepelin to DSM-V
R. Tandon, Gainesville, USA

S-01-003
Recent developments on the way to ICD-11
W. Gaebel, Düsseldorf, Germany

S-02
SYMPOSIA
11.30 – 13.00 h Harvard
Suicide and suicidal behavior in recent onset psychotic disorders
Chairs: I. Melle, Oslo, Norway
M. Nordentoft, Copenhagen, Denmark

S-02-001
Risk and suicidal behavior in recent onset psychotic disorders
M. Nordentoft, Copenhagen, Denmark
M. Pompili, P. Mortensen, C. Pedersen, T. M. Laursen

S-02-002
Development of suicidal behavior in first episode psychosis
I. Melle, Oslo, Norway

S-02-003
Self-disorders and suicidality in recent onset psychotic disorders
E. Haug, Ottestad, Norway

S-02-004
Insight, subjective experiences and suicidal behavior in first episode psychosis
E. Barrett, Oslo, Norway
### S-03 SYMPOSIA

**11.30 – 13.00 h**

**Stanford**

**Brain imaging in the early stages of schizophrenia**

Jointly organised by the Competence Network on Schizophrenia (CNS) and the Asian Network for Schizophrenia Research (ANSR)

**Chairs:** J. S. Kwon, Seoul, Republic of Korea  
O. Howes, London, United Kingdom

---

**S-03-001**

Structural and functional brain alterations in individuals at ultra-high risk for psychosis: an overview and future directions

J. S. Kwon, Seoul, Republic of Korea

**S-03-002**

Brain alterations and cognitive correlates in individuals at ultra-high risk psychosis

E. Meisenzahl, Munich, Germany  
N. Koutsouleris

**S-03-003**

Brain alterations in individuals at ultra-high risk for psychosis: emotional correlates

A. Aleman, Gronningen, The Netherlands  
E. Opmeer, E. Liemburg, R. Nieboer, L. Wunderink

**S-03-004**

Fronto-striatal interactions in individuals at ultra-high risk for psychosis

O. Howes, London, United Kingdom

### S-04 SYMPOSIA

**11.30 – 13.00 h**

**Princeton**

**Advances in animal models of schizophrenia: genes, environment, and prevention to biological foundations**

**Chairs:** J. Feldon, Zurich, Switzerland  
M. Pletnikov, Baltimore, USA

---

**S-04-001**

A mouse model for the study of synergistic interactions between prenatal immune activation and peri-pubertal stress in the development of schizophrenia-relevant disease

U. Meyer, Schwerzenbach, Switzerland  
S. Giovanni, J. Feldon

**S-04-002**

Prevention of schizophrenia-relevant brain and behavioral pathology by adolescent antipsychotic drug administration in an infection-based rat model of schizophrenia

I. Weiner, Tel-Aviv, Israel

**S-04-003**

DISC1 modulates immune response in the brain

M. Pletnikov, Baltimore, USA

**S-04-004**

Combining pharmacological and genetic approaches to animal models of schizophrenia: experimental approaches in dopamine receptor deficient mice

P. Moran, Nottingham, United Kingdom  
M. O’Callaghan, C. Bay-Richter, C. O’Tuathaigh, J. Waddington
P-01-001
Comparative effect of typical and atypical antipsychotic medication on cognitive functions in schizophrenia – cross-sectional study on patients admitted in a psychiatric unit in Bucharest in a 3 months period
A. I. Mihailescu, Bucharest, Romania
T. Donisan, B. Caval, M. Ilie, O. Dumitru

P-01-002
Impact on creativity of typical vs. atypical antipsychotic medication in schizophrenia – cross-sectional study on patients admitted in a psychiatric unit in Bucharest in a 3 months period
A. I. Mihailescu, Bucharest, Romania
B. Caval, T. Donisan, V. Volovici, R. Radu, O. Popa Velea

P-01-003
Comparative assessment of haloperidol and risperidone effect on neuromarkers and endothelium dysfunction indices in patients with the first psychotic episode
A. Vasilyeva, Chita, Russia
N. Govorin

P-01-004
Predicting dopamine D2 receptor occupancy following antipsychotic dose reduction: a pilot PET study
H. Uchida, Tokyo, Japan
R. Bies, T. Suzuki, A. Graff-Guerrero, B. Pollock, B. Mulsant, D. Mamo

P-01-005
Pharmacological daily dose and cognitive impairment in patients with schizophrenia spectrum disorders
D. Roesch-Ely, Heidelberg, Germany
M. Rehse, M. Bartolovic, D. Weigand, K. Rodelwald, M. Weisbrod

P-01-007
Treatment with haloperidol and changes in glucose values in patient with schizophrenia
O. Kozumplik, Zagreb, Croatia
S. Uzun, N. Mimica, M. Jakovljevic

P-01-008
Lamotrigine withdrawal associated worsening of positive symptoms in patients with schizophrenia
T. Szafranski, Warszawa, Poland

P-01-009
Post-hoc analysis from two randomised studies: efficacy, tolerability and dose-response of quetiapine XR 400/600/800MG/day in acute schizophrenia
A. H. Kalali, San Diego, USA
R. Kahn, U. Gustafsson, S. Nyberg

P-01-010
Norquetiapine and depressive symptoms in schizophrenia
H. Rasmussen, Glostrup, Denmark

P-01-011
Treatment with ziprasidone and changes in T in patient with schizophrenia
S. Uzun, Zagreb, Croatia
O. Kozumplik, N. Mimica, M. Jakovljevic

P-01-012
Evolution of function and sleep in a sample of schizophrenics patients during one year of treatment with extended-release paliperidone
A. Benito Ruiz, Toledo, Spain
L. Donaire, R. Ochoa, G. Lahera, A. Benito Ruiz
P-02 POSTER SESSIONS

13.30 – 14.30 h  Foyer

Co-morbidity
Chair:  B. Sabbe, Wilrijk, Belgium

P-02-001
Alcohol abuse and schizophrenia: possible predictors and consequences
S. Djrodjevic, Kovin, Serbia
L. Leposavic, D. Kernican

P-02-002
The relationship between baseline prepulse inhibition levels and ethanol withdrawal severity in rats
H. Kayir, Ankara, Turkey
O. Yavuz, G. Goktalay, M. Yildirim, T. Uzbay

P-02-003
Relationship between smoking cessation and gender in first psychotic patients after long-term follow-up
M. Martinez-Cengotitabengoa, Vitoria, Spain
S. Alberich, B. Garcia, S. Barbeito, M. Karim,
C. Valcarcel, A. Gonzalez-Pinto

P-02-004
The increasing comorbidities in schizophrenic patients
A. Dangellia, Tirana, Albania

P-02-006
Alexithymia and psychopathology in schizophrenia
S. van Geert, Gent, Belgium
S. Vanheule, R. Kessels, P. Naert

P-02-007
Suicidality level correlated with borderline personality traits in patients with depressive disorder and schizophrenia
A. Petek Eric, Osijek, Croatia
K. Dodig Urkovi, V. Kova, J. Ivanuši, P. Filakovi,
M. Petek

P-02-008
Suicidal ideation among schizophrenic patients
T. Rahim, Erbil, Iraq
B. Saeed

P-02-009
Metabolic syndrome in patients treated with antipsychotics: a follow-up study
P. Steylen, Venray, The Netherlands
F. van der Heijden, W. Verhoeven

P-02-011
Cardiovascular risk factors in patients with schizophrenia; do we detect and treat it?
A. Pose Cabarcos, Madrid, Spain
J. J. de Frutos Guijarro, F. Garcia Sánchez

P-02-012
Dental hygiene in schizophrenia: a large-scale cross-sectional survey
H. Tani, Asahi-Machi Nirasaki-Shi, Japan
T. Suzuki, Y. Shibuya, H. Shimanuki, K. Watanabe,
R. Den, M. Nishimoto, J. Hirana, H. Uchida

P-03 POSTER SESSIONS

13.30 – 14.30 h  Foyer

Neuroimaging
Chair:  W. Strik, Bern, Switzerland

P-03-001
Alterations of the brain reward system in antipsychotic naïve schizophrenic patients
M. Ø. Nielsen, Glostrup, Denmark
E. Rostrup, S. Wulff, S. Kapur, B. Glenthøj

P-03-002
Dopamine disturbances in relation to reward processing in schizophrenia
S. Wulff, Glostrup, Denmark
P-03-003  
Association of serum BDNF levels with hippocampal volumes in first psychotic episode drug-naïve schizophrenic patients  
E. Rizos, Athens, Greece  
M. Papathanasiou, P. Michalopoulou, A. Mazioti, A. Kastania, P. Nikolaidou, E. Laskos, V. Miranda, V. Kontaxakis, L. Lykouras

P-03-004  
Against an unitary view of schizophrenia: commonalities and differences of two phenotypes using connectivity fMRI  
J. Foucher, Strasbourg, France  
F. Berna, G. Stöber

P-03-005  
Dysfunctional neural networks of time perception in schizophrenia  
F. Ortuño, Pamplona, Spain  
J. Gómez, M. Valejío

P-03-006  
Task positive and task negative network in schizophrenia: decreased deactivation is related to structural deficits  
N. Pujol, Barcelona, Spain  
R. Penadés, R. Catalán, M. Bernardo, C. Junqué

P-03-007  
Contribution of the mirror neuron system to joint action perception  
B. Backasch, Marburg, Germany  
B. Straube, F. Klöhn-Saghatolislam, T. Kircher, D. Leube

P-03-008  
Auditory oddball P300 and 1H-magnetic resonance spectroscopy of the dorsolateral prefrontal cortex in young male patients with schizophrenia  
I. Lebedeva, Moscow, Russia  
N. Semenova, S. Sidorin, V. Kaleda, A. Barkhatova, E. Rumyantseva, T. Akhadov

P-03-009  
Auditory hallucinations in first episode psychotic subjects: a diffusion tensor imaging study of the arcuate fasciculus  
F. Marques-Teixeira, Porto, Portugal  
T. Reis Marques

P-03-010  
Hippocampal gray matter density correlates with disorganized symptoms in schizophrenia  
J. Siemerkus, Zurich, Switzerland  
I. Eva, R. Mirjana, L. Claudia, W. Godehard

P-03-011  
Increased midline noise power in the gamma band in schizophrenia related to negative symptoms, working memory deficit and insular activity  
V. Suazo, Salamanca, Spain  
V. Molina, A. Díez, C. Martín, A. Ballesteros, P. Casado, M. Martin loeches, P. Tamayo, C. Montes

P-03-012  
Combination of morphological features for recognition analysis of first-episode schizophrenia patients  
T. Kasparek, Brno, Czech Republic  
D. Schwarz, E. Janoušová, R. Prikryl, E. Češková

P-03-013  
Neural correlates of cognitive behavioral therapy effects in schizophrenia  
M. Cabanis, Marburg, Germany  
A. Krug, M. Pyka, H. Walter, W. Wölwer, B. Müller, G. Wiedemann, K. Vogeley, A. Wittorf, S. Klingberg, T. Kircher

P-03-014  
Structural brain correlates of sensorimotor gating in first-episode antipsychotic-naïve schizophrenia patients  
T. B. Hammer, Copenhagen, Denmark  
B. Oranje, A. Skimminge, B. Ebdrup, H. Bro, H. R. Siebner, B. Fagerlund, B. Glenthøj, W. Baare
Acta Psychiatrica Scandinavica

Contains high-quality scientific articles in English, representing clinical and experimental work in psychiatry. The journal acts as an international forum for the dissemination of information advancing the science and practice of psychiatry.

Original articles are welcomed, especially those that bring new knowledge or extend the present understanding of treatment. Equal priority is given to review articles and clinical overview articles.

Recent prominent authors include such world renowned researchers as: Leslie Citrome, Christoph U. Correll, Marc De Hert, Kenneth Kendler, Mario Maj, Gordon Parker, Stephen M. Stahl, David Taylor, Eduard Vieta and Jim van Os.

Topics covered in recent papers include:
• ADHD
• Autism
• Alzheimer disease
• Bipolar disorder
• Cannabis psychosis
• Depression
• Eating disorder
• Schizophrenia

To submit your next paper to Acta Psychiatrica Scandinavica, visit: http://mc.manuscriptcentral.com/actapsych

For author guidelines and further information visit: www.actapsychiatrica.com

Author Benefits:
• Quick and easy online submission - via ScholarOne Manuscripts
• Advanced article tracking - from submission through to acceptance and publication with Author Services
• Fast publication times - articles are available online weeks ahead of print publication
• Online Open - authors of articles in this journal can now choose to make their articles open access and available free for all readers through the payment of an author fee.
<table>
<thead>
<tr>
<th>S-05 SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.30 – 16.00 h</strong></td>
</tr>
<tr>
<td>Plenary Room</td>
</tr>
<tr>
<td>The future of psychiatric genetics beyond GWAS</td>
</tr>
<tr>
<td>Organised by the German Association for Psychiatry and Psychotherapy (DGPPN)</td>
</tr>
<tr>
<td>Chairs: P. Falkai, Göttingen, Germany</td>
</tr>
<tr>
<td>N.N.</td>
</tr>
</tbody>
</table>

| S-05-001 |
| The future of the GWAS  |
| T. Schulze, Göttingen, Germany  |

| S-05-002 |
| Proteomics and biomarkers  |
| D. Martins-de-Souza, Cambridge, United Kingdom  |

| S-05-003 |
| Back to the phenotype or endophenotype?  |
| O. Gruber, Göttingen, Germany  |

<table>
<thead>
<tr>
<th>S-06 SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.30 – 16.00 h</strong></td>
</tr>
<tr>
<td>Harvard</td>
</tr>
<tr>
<td>Efficacy and mechanisms of cognitive behavior therapy for psychosis: results of the POSITIVE network</td>
</tr>
<tr>
<td>Chairs: S. Klingberg, Tübingen, Germany</td>
</tr>
<tr>
<td>M. Wagner, Bonn, Germany</td>
</tr>
</tbody>
</table>

| S-06-001 |
| Cognitive behavioral therapy versus supportive therapy for persistent positive symptoms in psychotic disorders: major results of the POSITIVE study  |
| S. Klingberg, Tübingen, Germany  |
| A. Wittorf, C. Meisner, W. Wölwer, G. Wiedemann, J. Herrlich, A. Bechdolf, B. Müller, G. Sartory, M. Wagner, G. Buchkremer  |

| S-06-002 |
| The therapeutic alliance in CBT for pychoses: course and predictive value for outcome  |
| A. Wittorf, Tübingen, Germany  |
| S. Klingberg  |

| S-06-003 |
| Cognitive biases and cognitive deficits in patients with positive symptoms: relationship with symptoms and with symptom change during psychotherapy  |
| M. Wagner, Bonn, Germany  |

| S-06-004 |
| Cognitive behavior therapy in adolescents with persistent psychotic symptoms: results of randomised controlled trial  |
| A. Bechdolf, Cologne, Germany  |
### S-07 SYMPOSIA

**14.30 – 16.00 h**  
**Stanford**

**Insight in psychosis: cognitive and neural basis, and implications for treatment**

**Chairs:** A. Aleman, Groningen, The Netherlands  
A. David, London, United Kingdom

---

| S-07-001 | Is there a neurological basis for poor insight in schizophrenia?  
| A. David, London, United Kingdom  
N. Bedford, B. Wiffen, J. Gillean |

| S-07-002 | The association between self-reflective processing and insight in psychosis in schizophrenia patients: an fMRI study  
L. van der Meer, Groningen, The Netherlands  
M. Pijnenborg, A. Aleman |

| S-07-003 | Neuropsychological dysfunction and poor insight in psychosis  
A. Aleman, Groningen, The Netherlands  
P. Quee, R. Bruggeman, M. Pijnenborg |

| S-07-004 | Treatment of insight in schizophrenia: meta-analysis  
M. Pijnenborg, Assen, The Netherlands  
R. Donkersgoed, A. Aleman |

### S-08 SYMPOSIA

**14.30 – 16.00 h**  
**Princeton**

**Neuroprotective strategies in schizophrenia**

**Chairs:** J. Priller, Berlin, Germany  
T. Wüstenberg, Berlin, Germany

---

| S-08-001 | Neuroprotection in schizophrenia: novel candidates and perspectives  
J. Priller, Berlin, Germany |

| S-08-002 | Brain-derived neurotrophic factor: also playing a neuroprotective role in schizophrenia?  
R. Hellweg, Berlin, Germany |

| S-08-003 | EPO treatment preserves gray matter in discrete brain regions of chronic schizophrenic patients  
T. Wüstenberg, Berlin, Germany  

| S-08-004 | EPO: a new treatment for cognitive dysfunction and depressive symptoms in patients with affective disorder?  
K. Miskowiak, Copenhagen, Denmark |

### W-01 WORKSHOPS

**14.30 – 16.00 h**  
**Yale 2**

**MedicaWiki: a webbased independant evidence based psychopharmacological prescription decision system – “decide & prescribe”**

**Chair:** W. Broekema, Amersfoort, The Netherlands
SCIENTIFIC PROGRAMME – Thursday, 29 September 2011

S-09 SYMPOSIA
16.30 – 18.00 h Plenary Room
Novel therapeutic targets for treating schizophrenia
Chairs: W. Maier, Bonn, Germany
H.-J. Möller, Munich, Germany

S-09-001
Novel approaches for treating schizophrenia
G. Gründer, Aachen, Germany

S-09-002
Methodological challenges of demonstrating cognitive improvements with broad spectrum agents: a novel approach
A. H. Kalali, San Diego, USA

S-09-003
Selective phosphodiesterase inhibitors as a target for cognition enhancement in schizophrenia
J. Prickaerts, Maastricht, The Netherlands

S-09-004
LY2140023 Monohydrate: preclinical and clinical update on the development of a mGluR2/3 agonist treatment for schizophrenia
J.-C. Gomez, Indianapolis, USA

S-10 SYMPOSIA
16.30 – 18.00 h Harvard
Cognitive behaviour therapy for psychosis: what do we know about its effectiveness and neural correlates?
Chairs: T. Kircher, Marburg, Germany
T. Lincoln, Marburg, Germany

S-10-001
The effects of CBT in persons with ultra high risk: the Dutch EDIE trial
M. van der Gaag, Amsterdam, The Netherlands

S-10-002
Targeting social and symptomatic outcomes using CBT for psychosis: effectiveness, strategies and mediators
D. Fowler, Norwich, United Kingdom

S-10-003
Effectiveness of CBT in a German outpatient setting. Short and long term results of a controlled randomised trial
T. Lincoln, Marburg, Germany
M. Ziegler, S. Mehl, E. Luellmann, M.-L. Kesting, S. Westermann, W. Rief

S-10-004
How does CBT effect the brain of patients of schizophrenia: a multicenter fMRI study
T. Kircher, Marburg, Germany
O-01 ORAL PRESENTATIONS
16.30 – 18.00 h Stanford
Co-morbidity
Chairs: N. Sartorius, Geneva, Switzerland
A. G. Awad, Toronto, Canada

O-01-001
Is it time to consider comorbid substance abuse in schizophrenia as a dimension and indication for new antipsychotic drug development
A. G. Awad, Toronto, Canada

O-01-002
Cardiovascular risk factors in patients treated with antipsychotics: a follow-up study
P. Steylen, Venray, The Netherlands
F. van der Heijden, W. Verhoeven

O-01-003
Relationship between functionality and metabolic syndrome in schizophrenia
J. M. Pelayo Teran, Madrid, Spain

O-01-004
Long term maintenance of weight loss in patients with severe mental illness through a behaviour programme in the UK. Results at 10 years of follow up
J. Pendlebury, Manchester, United Kingdom
R. Holt, H. Wildgust, C. Bushe

O-01-005
Cancer co-mortality profile in schizophrenia and psychotic disorders
V. Ajdacic-Gross, Zurich, Switzerland
A. Tschopp, M. Bopp, F. Gutzwiller, W. Rössler

O-01-006
Panic attacks, alexithymia and hallucinations in schizophrenia
S. van Geert, Gent, Belgium
S. Vanheule, R. Kessels, P. Naert

S-11 SYMPOSIA
16.30 – 18.00 h Princeton
Motor symptoms as an intrinsic component of schizophrenia pathobiology
Chairs: S. Walther, Bern, Switzerland
J. Waddington, Dublin, Ireland

S-11-001
Spontaneous involuntary movements as an integral component of network dysfunction in schizophrenia
J. Waddington, Dublin, Ireland
K. Tomiyama, N. Koshikawa

S-11-002
Dyskinesia and parkinsonism in antipsychotic naïve schizophrenia, first-degree relatives and controls; prevalence and methods of measurement
J. Koning, Amersfoort, The Netherlands

S-11-003
Neuromotor abnormalities in first-episode psychosis patients: status at antipsychotic naïve state and response to anti-psychotic drugs
M. J. Cuesta, Pamplona, Spain

S-11-004
Neurobiology and clinical correlates of quantitative motor activity in schizophrenia
S. Walther, Bern, Switzerland
S-12 SYMPOSIA
08.30 – 10.00 h  Plenary Room
Negative symptoms of schizophrenia: assessment, domains and relationships with outcome
Chairs: S. Galderisi, Naples, Italy
W. Gaebel, Düsseldorf, Germany

S-12-001
Assessment of negative symptoms in schizophrenia
B. Kirkpatrick, Temple, USA

S-12-002
Are abnormalities of reward processing a key component of negative symptoms in schizophrenia?
F. Schlagenhauf, Berlin, Germany
G. Juckel, A. Heinz

S-12-003
The relationship between negative symptoms and neuropsychological impairment across psychotic disorders
A. Reichenberg, London, United Kingdom
M. Russo

S-12-004
Persistent negative symptoms in first episode psychosis patients
S. Galderisi, Naples, Italy
A. Mucci

S-13 SYMPOSIA
08.30 – 10.00 h  Harvard
Antipsychotics in the elderly
Chairs: W. Maier, Bonn, Germany
C. Turrina, Brescia, Italy

S-13-001
Antipsychotics in treatment of behavioral and psychological symptoms in dementias
P. H. Robert, Nice, France
E. Mulin, R. David

S-13-002
Pharmacotherapy of neuropsychiatric symptoms in dementia in nursing homes
M. Rapp, Berlin, Germany
T. Majic, J.-P. Pluta, T. Mell, J. Kalbitzer, Y. Treusch, A. Heinz, H. Gutzmann

S-13-003
Vascular side effects of neuroleptics and their prevention
C. Turrina, Brescia, Italy
E. Sacchetti

S-13-004
Use of antipsychotics in the elderly: regulatory aspects
K. Broich, Bonn, Germany
SCIENTIFIC PROGRAMME – Friday, 30 September 2011

S-14 SYMPOSIA
08.30 – 10.00 h Stanford
Glutamate dysfunction in schizophrenia and bipolar disorder: evidence from genetics and brain imaging
Chairs: J. Gallinat, Berlin, Germany
D. Rujescu, Munich, Germany

S-14-001
GWAS, sequencing, systems biology, gene-environment studies: how to navigate through the jungle of contemporary psychiatric genetics
T. Schulze, Göttingen, Germany

S-14-002
Gamma oscillations, cognition and interaction of glutamatergic and GABAergic neurons
C. Mulert, Hamburg, Germany

S-14-003
Glutamatergic genes of schizophrenia and neuropsychological intermediate phenotypes
D. Rujescu, Munich, Germany

S-14-004
Dysfunction of dopamine-glutamate interaction: evidence from multimodal imaging
J. Gallinat, Berlin, Germany
M. Schäfer, F. Schubert

O-02 ORAL PRESENTATIONS
08.30 – 10.00 h Princeton
Epidemiology and clinical phenotypes
Chairs: A. David, London, United Kingdom
P. Bebbington, London, United Kingdom

O-02-001
COMT genotype and poor cognition is associated with a negative/disorganised schizophrenia subtype
M. Green, Darlinghurst, Australia
M. Dragovic, A. Jablensky, M. Cairns, P. Tooney, R. Scott, C. Loughland, V. J. Carr

O-02-002
Psychosis dimensions and corollary scales in young and middle-aged adults in Zurich
V. Ajdacic-Gross, Zürich, Switzerland
M. P. Hengartner, K. Landolt, S. A. Rodgers, M. Müller, I. Warnke, W. Kawohl, W. Rössler

O-02-003
Neurocognitive features in subgroups of bipolar disorder
S. R. Aminoff, Oslo, Norway
T. Hellvin, T. V. Lagerberg, A. O. Berg, O. A. Andreassen, I. Melle

O-02-004
Schizophrenia and autism – overlap and difference
M. Fitzgerald, Dublin, Ireland

O-02-005
Midlife progression and its clinical correlates in schizophrenia: a 43-year follow-up in the Northern Finland 1966 birth cohort
M. Isohanni, Oulu, Finland
E. Jääskeläinen, A. Alaräisänen, I. Isohanni, J. Miettunen

O-02-006
What is the standard of living among clients in community early intervention programs?
Data from the Matryoshka Project
C. Cheng, Thunder Bay, Canada
C. S. Dewa, L. Trojanowski, D. Loong
### S-15 SYMPOSIA

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| S-15-001 | 10.30 – 12.00 h | Plenary Room | Brain circuits involved in thought and movement disorders | W. Strik, Bern, Switzerland  
S. Walther |
| S-15-002 | 10.30 – 12.00 h | Plenary Room | Brain–behaviour relation of emotion in schizophrenia | F. Schneider, Aachen, Germany |
| S-15-003 | 10.30 – 12.00 h | Plenary Room | New approaches to cognitive remediation | A. Medalia, New York, USA |
| S-15-004 | 10.30 – 12.00 h | Plenary Room | Integrated cognitive therapies: update and perspective | V. Roder, Bern, Switzerland  
S. J. Schmidt, D. R. Müller |

### S-16 SYMPOSIA

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| S-16-001 | 10.30 – 12.00 h | Harvard | EPA position statements concerning schizophrenia and beyond | H.-J. Möller, Munich, Germany  
M. de Hert, Kortenberg, Belgium |
| S-16-002 | 10.30 – 12.00 h | Harvard | Quality of mental health | W. Gaebel, Düsseldorf, Germany |
| S-16-003 | 10.30 – 12.00 h | Harvard | Prevention of mental illness and promotion of mental health | D. Bhugra, London, United Kingdom |
| S-16-004 | 10.30 – 12.00 h | Harvard | Cardiovascular disease in people with severe mental illness | M. de Hert, Kortenberg, Belgium |
| S-16-005 | 10.30 – 12.00 h | Harvard | Value of antidepressants in the treatment of unipolar depression | H.-J. Möller, Munich, Germany |

**Cognition in schizophrenia: from neural mechanisms to psychological interventions**

Chairs:  
W. Strik, Bern, Switzerland  
V. Roder, Bern, Switzerland
<table>
<thead>
<tr>
<th>S-17</th>
<th>SYMPOSIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Stanford</td>
</tr>
<tr>
<td>Social cognition and violent behavior in schizophrenia</td>
<td></td>
</tr>
<tr>
<td>Chairs: W. Wölwer, Düsseldorf, Germany</td>
<td>S. Hodgins, London, United Kingdom</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-17-001</th>
<th>Violent behavior among people with schizophrenia: a framework for investigations of causes, prevention and treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Hodgins, London, United Kingdom</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-17-002</th>
<th>Social cognition and violence in schizophrenia: is there a link?</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Brüne, Bochum, Germany</td>
<td>E. Brown</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-17-003</th>
<th>Childhood disruptive behavior disorders: phenotypes, neuropsychiatric predictors, and genetic background effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Kerekes, Gothenburg, Sweden</td>
<td>S. Lundström, P. Jern, A. Tajnia, S. Brändström, M. Råstam, P. Lichtenstein, H. Anckarsäter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S-17-004</th>
<th>Disturbed social cognition as a treatment target in schizophrenia patients with a history of violence</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Frommann, Düsseldorf, Germany</td>
<td>F. Lüneborg, S. Strath, J. Brinkmeyer, C. Luckhaus, W. Wölwer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03</th>
<th>ORAL PRESENTATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.30 – 12.00 h</td>
<td>Princeton</td>
</tr>
<tr>
<td>Early stages of schizophrenia</td>
<td></td>
</tr>
<tr>
<td>Chairs: S. Ruhrmann, Cologne, Germany</td>
<td>R. K. R. Salokangas, Turku, Finland</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-001</th>
<th>The period of prodromal symptoms to acute phase of illness: untreated schizophrenia</th>
</tr>
</thead>
<tbody>
<tr>
<td>G. Bogojevic, Belgrade, Serbia</td>
<td>L. Žiravac</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-002</th>
<th>Duration of untreated psychosis and its relation to outcome in schizophrenia within the Northern Finland 1966 birth cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Penttilä, Oulu, Finland</td>
<td>J. Miettunen, H. Koponen, J. Veijola, M. Isohanni, E. Jääskeläinen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-003</th>
<th>How does childhood adversity impact on schizophrenia? Findings from the Australian Schizophrenia Research Bank (ASRB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. McCabe, Darlinghurst, Australia</td>
<td>E. Moloney, H. Stain, C. Loughland, V. Carr</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-004</th>
<th>Severe social anxiety in early psychosis is associated with poor premorbid functioning, depression and reduced quality of life</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. L. Romm, Oslo, Norway</td>
<td>I. Melle, C. Thoresen, O. A. Andreassen, J. I. Røssberg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-005</th>
<th>Fullness of life reduces risk of psychosis in high-risk patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. K. R. Salokangas, Turku, Finland</td>
<td>M. Heinimaa, S. Luutonen, J. Klosterkötter, S. Ruhrmann, H. Graf von Reventlow, D. Linszen, M. Birchwood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>O-03-006</th>
<th>Indicated prevention with Omega-3 fatty acids in young people with ‘at-risk-mental-state’ for psychosis: design of a 5-year follow-up</th>
</tr>
</thead>
</table>
PL-02  PLENARY LECTURES
12.15 – 13.00 h  Plenary Room
Schizophrenia treatment and prevention – facts and visions
Chair: A. G. Awad, Toronto, Canada

PL-02-001
Schizophrenia treatment and prevention – facts and visions. Providing the best treatment today and developing better treatments for tomorrow
R. Tandon, Gainesville, USA

P-04  POSTER SESSIONS
13.30 – 14.30 h  Foyer
Epidemiology, diagnosis
Chair: D. Bhugra, London, United Kingdom

P-04-001
The epidemiology of schizophrenia and other psychotic disorders among Finnish prisoners
M. Joukamaa, Tampere, Finland
J. Aarnio, S. Hakomäki, T. Lintonen, A. Mattila, H. Vartiainen, P. Viitanen, T. Wuolijoki

P-04-002
Temperament in individuals with psychotic disorders before and after the onset of illness
J. Miettunen, Oulu, Finland
P. Juola, E. Roivainen, J. Veijola, A. Alaräisänen, M. Isohanni, E. Jääskeläinen

P-04-003
A new epidemiological survey on stress, mental health and psychotic symptoms in young and middle-aged adults in Zurich
S. A. Rodgers, Zurich, Switzerland
M. P. Hengartner, V. Ajdacic-Gross, K. Landolt, M. Müller, I. Warnke, W. Kawohl, W. Rössler

P-04-004
Concordance rates and early risk factors in schizophrenia; a set-up for a twin study, including preliminary data on concordance rates from linking the Danish Twin Register and the Danish Psychiatric Central Register
R. Hilker, Glostrup, Denmark
B. Fagerlund, K. Christensen, M. Nordentoft, B. Glenthøj

P-04-005
Does reduced facial affect bias clinicians to overrate depression in patients with schizophrenia? Prevalence and explanatory factors of disconcordance between self- and observer rated depression in schizophrenia
M. Hartmann, Hamburg, Germany
T. Lincoln

P-04-006
Cycloid psychoses: where are they in ICD-10 and DSM-IV?
N. van de Kerkhof, Venray, The Netherlands
M. Schneider, F. van der Heijden, W. Verhoeven, G. Stöber

P-04-007
Klinefelter syndrome in a male identical twin and chronic schizophrenia-like psychosis
W. Verhoeven, Venray, The Netherlands
J. Egger, E. Wingbermühle, N. van de Kerkhof

P-04-008
Psychiatric disorders in children with cerebral palsy
C. Bertoncelli, Nice, France
D. Bertoncelli

P-04-009
Influence of child and adolescent psychiatric disorders on neurological development pathologies
C. Bertoncelli, Nice, France
M. Bertoncelli

P-04-010
Psychosis in herpes encephalitis
J. de Santiago, Barcelona, Spain
A. Sánchez Peña
P-05-001
The Australian Schizophrenia Research Bank (ASRB): the first 650 sample profile
C. Loughland, Darlinghurst, Australia
K. McCabe, S. Catts, A. Jablensky, F. Hensken, P. Michie, V. Carr, P. Tooney

P-05-002
Association of Dystrobrevin-binding protein 1 gene with cognitive functioning in schizophrenic patients
G. Bakanidze, Berlin, Germany
C. Hutzler, F. Auraß, S. Onken, M. Rapp, I. Puls

P-05-004
Genome-wide significant association with negative mood delusions in 3q26.1
S. Meier, Mannheim, Germany
J. Strohmaier, J. Frank, J. Treutlein, R. Breuer, M. Mattheisen, T. Mühleisen, S. Cichon, M. Nöthen, M. Rietschel

P-05-005
Early visual processing measured with backward masking: The new endophenotype of schizophrenia?
G. Bakanidze, Berlin, Germany
M. Roinishvili, E. Chkonia, M. Herzog, A. Brand, I. Puls

P-05-006
Association of polymorphisms rs2055314, rs2272522 and rs331894 in close homologue of L1 gene with schizophrenia in state of Qatar
N. Rizk, Doha, Qatar
K. Abdulla Al-ali, A. Alkaseri, S. Zainul Abdeen, E. Jose, T. Shaltout

P-05-007
Association of the CTLA-4 gene with schizophrenia in Coimbatore, South Indian population
P. Manikantan, Coimbatore, India
V. Balachnadar, K. Sasikala, S. Mohanadevi

P-05-008
DTNBP1, HSPs and TAAR6 variations influence schizophrenic phenotype and treatment response
T. Jun, Seoul, Republic of Korea
C. U. Pae, H. R. Wang, H. R. Song, Y. S. Woo, W.-M. Bahk

P-05-009
Protein of metabotropic glutamate receptor has been detected in plasma of blood in schizophrenia
L. Smirnova, Tomsk, Russia
L. Loginova

P-05-010
CB2 cannabinoid receptor is involved in schizophrenia-like behaviours
F. Navarrete Rueda, San Juan De Alicante, Spain
A. Ortega-Alvaro, A. Aracil-Fernandez, M. Garcia Gutierrez, J. Manzanares Robles

P-05-011
Ketamine affects gene expression of key brain molecules at crossroads of glucose metabolism and neurotoxicity: possible implications in psychosis
C. Tomasetti, Naples, Italy
A. de Bartolomeis, F. Iasevoli, G. Latte, R. Rossi
P-06

POSTER SESSIONS
13.30 – 14.30 h Foyer

Neurobiology
Chair: C. Höschl, Prague, Czech Republic

P-06-001
White blood cell count in first episode non-smoking patients
C. Garcia Rizo, Barcelona, Spain
E. Fernandez-Egea, C. Olivera, M. Bernardo, B. Kirkpatrick

P-06-002
Influence of acute psychosis on breathing regulation and its impact on heart rate variability
T. Rachow, Jena, Germany
S. Berger, A. K. Israel, K. Bär

P-06-003
Peripheral endothelial dysfunction in patients suffering from acute schizophrenia: a potential marker for cardiovascular morbidity?
A. K. Israel, Jena, Germany
S. Berger, T. Rachow, A. Voss, K. Bär

P-06-004
Catalytic activity of abzymes in patients with schizophrenia with movement disorders was increased
L. Smirnova, Tomsk, Russia
N. Fattahov

P-06-005
Oxidative and inflammatory status in first-episode psychoses and its relationship with cognitive impairment
M. Martinez-Cengotitabengoa, Vitoria, Spain
A. Ugarte, M. Fernandez, P. Vega, M. Saenz, I. Zorrilla, A. Gonzalez-Pinto

P-06-006
Methods and composition for modulation of activity of voltage gated ion channels
A. Elayyan, Amman, Jordan

P-06-007
The synesthetic phenomenology in the schizophrenic organization
E. Venga, Naples, Italy
D. Venga

P-06-008
Alterations in hippocampal function in a maternal immune activation animal model of schizophrenia
A. Wolff, Dunedin, New Zealand
D. Dickerson, D. Bilkey

P-06-009
Clozapine administration ameliorates disrupted prefrontal–hippocampal synchrony in an animal model of schizophrenia
D. Dickerson, Dunedin, New Zealand
A. Restieaux, D. Bilkey

P-06-010
Impaired cortical excitability in schizophrenia is related to the disease course – a cross-sectional study
A. Hasan, Göttingen, Germany
P-07-001
In-vivo pharmacological evaluation of novel olanzapine analogues in rat: potential novel antipsychotic drugs with lower obesogenic effect
S. Jafari, Wollongong, Australia
F. Fernandez, X.-F. Huang

P-07-002
Neurobehavioral adaptations to steady state dose of haloperidol associated to treatment efficacy and failure
D. Amato, Erlangen, Germany
S. Natesan, L. Yavich, S. Kapur, C. Mueller

P-07-003
Comparative study on animal model of neuroprotection and cardioprotection for long-acting antipsychotics
D. Marinescu, Craiova, Romania
L. Mogoanta, I. Udristoiu, I. Marinescu, M. C. Pirlog, D. Pirici

P-07-004
The effect of cannabidiol in a MK-801-induced rat model of aspects of schizophrenia
A. Gururajan, Melbourne, Australia
D. Taylor, D. Malone

P-07-005
Attention deficit induced by deletion of CB1 cannabinoid receptor is not reversed by haloperidol and risperidone treatment in the prepulse inhibition test
A. Ortega-Alvaro, Albacete, Spain
A. Ternianov, J. Manzanares

P-07-006
T-817MA, a novel neurotrophic agent, prevents loss of GABAergic parvalbumin-positive neurons and sensorimotor gating deficits in rats transiently exposed to MK-801 in the neonatal period
T. Uehara, Toyama, Japan

P-07-007
Effects of risperidone on development and expression of nicotine-induced locomotor sensitization in rats
T. Uzbay, Ankara, Turkey
E. Akdag, H. Kayir

P-07-008
Effects of cannabidiol on schizophrenia-like behavioral deficits presented by spontaneously hypertensive rats (shr)
R. Levin, Sao Paulo, Brazil
V. Almeida, M. Calzavara, F. Peres, S. Niigaki, J. Hallak, A. Zuardi, J. A. Crippa, V. Abilio

P-07-009
New hydroxysulfonamide with analgesic, anticonvulsant and tranquilizer activity
H. Zlenko, Dnipropetrovsk, Ukraine
L. Kasyan, V. Palchikov, I. Prishlyak
**W-02**

**WORKSHOPS**

14.30 – 16.00 h  
Plenary Room

**Past, current and future European schizophrenia research projects**

*Chairs: W. Gaebel, Düsseldorf, Germany  
S. Galderisi, Naples, Italy*

**W-02-001**

Transition and beyond – findings of the European prediction of psychosis study (EPOS)

*S. Ruhrmann, Cologne, Germany  
F. Schultze-Lutter, R. K. Salokangas, D. Linszen,  
M. Birchwood, G. Juckel, A. Heinz, S. Lewis,  
A. Morrison, J. Klosterkötter*

**W-02-002**

Novel methods leading to new medications in depression and schizophrenia (NEWMEDS)

*A. Reichenberg, London, United Kingdom*

**W-02-003**

European twin study network on schizophrenia (EUTwinsS)

*I. Nenadic, Jena, Germany  
H. Sauer*

**W-02-004**

Genomic variations underlying common behavior diseases and cognition trait in human populations (ADAMS)

*A. Papassotiropoulos, Basel, Switzerland*

**O-04**

**ORAL PRESENTATIONS**

14.30 – 16.00 h  
Harvard

**Drug and other somatic treatments**

*Chairs: J. Libiger, Hradec Kralove,  
Czech Republic  
W. Cahn, Utrecht, The Netherlands*

**O-04-002**

Dopamine D2 receptor occupancy with risperidone or olanzapine needed for the maintenance treatment of schizophrenia: a cross-sectional study

*Y. Mizuno, Kawasaki, Japan  
R. R. Bies, G. Remington, D. C. Mamo, T. Suzuki,  
B. G. Pollock, T. Tsuboi, H. Takeuchi, M. Mimura,  
H. Uchida*

**O-04-003**

Mentalizing skills deficits in schizophrenia as a cue for drug choice? Clozapine vs other antipsychotic profiles on keeping outpatients stable

*R. Duñó, Barcelona, Spain  
K. Langohr, D. Palao, A. Tobeña*

**O-04-004**

Neuroleptic-induced movement disorders: a cross-cultural perspective

*E. Pi, Los Angeles, USA*

**O-04-005**

A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM® in healthy subjects

*I. Gutierrez, Granada, Spain  

**O-04-006**

Effect of cardiovascular exercise on global brain volumes in patients with schizophrenia and matched healthy controls

*T. Scheewe, Utrecht, The Netherlands  
N. van Haren, G. Sarkisyan, T. Takken, H. Hulshoff Pol, F. Backx, R. Kahn, W. Cahn*
S-18  SYMPOSIA
14.30 – 16.00 h  Stanford
Schizophrenia – a mild encephalitis?
Chairs: K. Bechter, Günzburg, Germany
N. Müller, Munich, Germany

S-18-001
The mild encephalitis hypothesis, specified for schizophrenia based on CSF investigation
K. Bechter, Günzburg, Germany

S-18-002
Inflammation in schizophrenia: results from neuropathological studies
B. Bogerts, Magdeburg, Germany

S-18-003
Neuroinflammation in schizophrenia: a PET study
H. C. Klein, Groningen, The Netherlands
J. Doorduin, R. Dierckx, I. Jonker, E. de Vries

S-18-004
Therapeutic consequences of inflammation in schizophrenia
N. Müller, Munich, Germany

S-19  SYMPOSIA
14.30 – 16.00 h  Princeton
Psychomotor symptoms in schizophrenia
Chairs: M. Morrens, Wilrijk, Belgium
B. Sabbe, Wilrijk, Belgium

S-19-001
Neural correlates of psychomotor functioning in schizophrenia
L. Docx, Wilrijk, Belgium

S-19-002
The impact of negative and depressive symptoms on psychomotor functioning in schizophrenia
M. Morrens, Wilrijk, Belgium

S-19-003
State and trait aspects of section monitoring in schizophrenia
E. de Bruijn, Nijmegen, The Netherlands

S-19-004
The effect of nicotine on cognitive and psychomotor functioning in smoking and non smoking schizophrenic patients
C. Quisenaerts, Wilrijk, Belgium

W-03  WORKSHOPS
14.30 – 17.30 h  Yale 2
Writing manuscripts for publication in English language scientific journals: a workshop
Chair:  S. Hodgins, London, United Kingdom
**S-20**

**SYMPOSIA**

16.30 – 18.00 h  
**Plenary Room**

**Toxicity of relapse**

*Chairs: C. Höschl, Prague, Czech Republic*  
*M. Birchwood, Birmingham, United Kingdom*

**S-20-001**

**Anatomy of relapse**

*M. Birchwood, Birmingham, United Kingdom*

**S-20-002**

**Disorganisation and its association with progressive brain volume changes in schizophrenia**

*W. Cahn, Utrecht, The Netherlands*  
*G. Collin, E. Derks, N. van Haren, H. Schnack, H. Hulshoff Pol, R. Kahn*

**S-20-003**

**Relapses of schizophrenia and structural changes in the brain**

*N. van Haren, Utrecht, The Netherlands*

**S-20-004**

**ITAREPS: information technology aided relapse prevention programme in schizophrenia**

*F. Spaniel, Prague, Czech Republic*

---

**S-21**

**SYMPOSIA**

16.30 – 18.00 h  
**Harvard**

**Co-morbidity of schizophrenia and physical illness**

*Chairs: N. Sartorius, Geneva, Switzerland*  
*W. Gaebel, Düsseldorf, Germany*

**S-21-001**

**Review of evidence concerning co-morbidity of schizophrenia and physical illness**

*M. de Hert, Kortenberg, Belgium*

**S-21-002**

**Excess mortality, causes of death and life expectancy in main groups of patients with recent onset of mental disorders in 2000-2006 in Denmark, Finland and Sweden**

*M. Nordentoft, Copenhagen, Denmark*  
*K. Wahlbeck, M. Gissler, J. Westman, H. Alinaghizadeh, T. M. Laursen*

**S-21-003**

**Co-morbidity of schizophrenia and physical illness**

*H. Parmentier, Purley, United Kingdom*
SCIENTIFIC PROGRAMME – Friday, 30 September 2011

S-22 SYMPOSIA
16.30 – 18.00 h Stanford
Advances in understanding the causes of schizophrenia
Chairs: R. Mössner, Bonn, Germany
D. Rujescu, Munich, Germany

S-22-001
New genetic findings in schizophrenia
D. Rujescu, Munich, Germany

S-22-002
The genetics of sensorimotor gating: a core endophenotype of schizophrenia
B. Quednow, Zurich, Switzerland

S-22-003
Unraveling the pharmacogenomics of schizophrenia
R. Mössner, Bonn, Germany

S-22-004
Imaging genetics in schizophrenia
H. Walter, Berlin, Germany

S-23 SYMPOSIA
16.30 – 18.00 h Princeton
PREVENT: a multidimensional study of people at risk to develop first episode psychosis – from the metabolic syndrome to the efficacy of CBT
Chairs: A. Bechdolf, Cologne, Germany
J. Klosterkötter, Cologne, Germany

S-23-001
Cortical excitability in people at risk of psychosis
T. Wobrock, Göttingen, Germany

S-23-002
Stress experience and stress sensitivity in subjects at risk for psychosis
M. Wagner, Bonn, Germany
J. Drees, T. Lataster, A. Bechdolf, I. Myin-Germeys

S-23-003
Prevalence of the metabolic syndrome in men and women at risk of psychosis
J. Cordes, Düsseldorf, Germany

S-23-004
Dysfunctional cognitive and emotional empathy in the prodromal phase of schizophrenia
J. Gallinat, Berlin, Germany
C. Montag, Y. Gudowski
### S-24 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| 18.15 – 19.45 h | Harvard           | Strength based treatment in an early psychosis ACT team: engaging the trouble-some avoiders | B. Jacobsen, Nijmegen, The Netherlands  
M. Elfrink, Nijmegen, The Netherlands |

#### S-24-001

ACT and recovery – a new perspective on treatment for early psychosis. The first three years: qualitative and quantitative data  
M. Elfrink, Nijmegen, The Netherlands

#### S-24-002

The daily teamwork: what, how, with whom and why  
B. Jacobsen, Nijmegen, The Netherlands

#### S-24-003

ACT approach, substance abuse, psychosis and recovery  
M. van Niekerk, Nijmegen, The Netherlands

#### S-24-004

Medication: on the road to shared decision making  
B. Jacobsen, Nijmegen, The Netherlands

### S-25 SYMPOSIA

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
</table>
| 18.15 – 19.45 h | Stanford         | Psychotic symptoms in schizophrenia – biological correlates, clinical outcome and therapeutic consequences | R. Schennach-Wolff, Munich, Germany  
C. Mulert, Hamburg, Germany |

#### S-25-001

Biological causes of psychotic symptoms such as auditory verbal hallucinations (AVH) – DTI and EEG phase coherence results  
C. Mulert, Hamburg, Germany

#### S-25-002

Different patterns of response to psychotic symptoms in schizophrenia patients – implications for clinical practice  
M. Jäger, Günzburg, Germany

#### S-25-003

Occurrence and treatment of residual symptoms in schizophrenia  
R. Schennach-Wolff, Munich, Germany  

#### S-25-004

Metacognitive training – latest results on its efficacy in treating psychotic symptoms in schizophrenia patients  
S. Moritz, Hamburg, Germany
O-05-001
Is social cognitive remediation therapy effective in the treatment of schizophrenia patients?
D. R. Müller, Bern, Switzerland
S. J. Schmidt, V. Roder

O-05-002
Mechanisms of functional recovery in Cognitive Remediation Therapy for schizophrenia patients
S. J. Schmidt, Bern, Switzerland
D. R. Müller, V. Roder

O-05-003
Remediation of social cognition deficits in schizophrenia: a proof of concept pilot study using biofeedback
K. McCabe, Darlinghurst, Australia
C. Loughland, T. Lewin, M. Hunter, V. Carr

O-05-004
Cognitive psychotherapy in early psychosis: metacognition and disorders remission
R. Popolo, Rome, Italy
M. Procacci, G. Salvatore, G. Dimaggio

O-05-005
The Opus-trial: Intensive, early, psychosocial intervention versus treatment as usual for first-episode psychosis patients. Results from the 10-year follow-up
R. G. Secher, Copenhagen, Denmark
S. F. Austin, N. P. O. Mors, M. Nordentoft

O-05-006
Day clinic treatment and recovery in patients with schizophrenia
I. Sibitz, Vienna, Austria
M. Lipp
<table>
<thead>
<tr>
<th>Symposium</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-26-001</td>
<td>Time-series based analysis of integrative psychotherapy of psychosis</td>
<td>08.30 – 10.00 h</td>
<td>Plenary Room</td>
</tr>
<tr>
<td>S-26-002</td>
<td>The role of Cognitive Behavioral Therapy and Cognitive Remediation for the treatment of negative symptoms</td>
<td>08.30 – 10.00 h</td>
<td>Plenary Room</td>
</tr>
<tr>
<td>S-26-003</td>
<td>What are the therapeutic ingredients of cognitive behaviour therapy for psychosis? A systematic review</td>
<td>08.30 – 10.00 h</td>
<td>Plenary Room</td>
</tr>
<tr>
<td>S-26-004</td>
<td>CBT in persistent psychotic symptoms affects functioning and suffering</td>
<td>08.30 – 10.00 h</td>
<td>Plenary Room</td>
</tr>
<tr>
<td>S-27-001</td>
<td>The EIS-concept in UK and recent findings from the youth-SPACE project</td>
<td>08.30 – 10.00 h</td>
<td>Harvard</td>
</tr>
<tr>
<td>S-27-002</td>
<td>Programma2000 – concept and practical experience</td>
<td>08.30 – 10.00 h</td>
<td>Harvard</td>
</tr>
<tr>
<td>S-27-003</td>
<td>The TIPS-concept and recent findings</td>
<td>08.30 – 10.00 h</td>
<td>Harvard</td>
</tr>
<tr>
<td>S-27-004</td>
<td>OPUS: concept and recent findings</td>
<td>08.30 – 10.00 h</td>
<td>Harvard</td>
</tr>
<tr>
<td>S-27-005</td>
<td>Specialised first episode psychosis services: are they worth it?</td>
<td>08.30 – 10.00 h</td>
<td>Harvard</td>
</tr>
</tbody>
</table>
S-28  SYMPOSIA
08.30 – 10.00 h  Stanford
Dopaminergic and glutamatergic dysfunction in schizophrenia
Chairs: A. Heinz, Berlin, Germany
N.N.

S-28-001
The influence of risk genes on the glutamate system in schizophrenia: evidence from post-mortem studies
A. Schmitt, Göttingen, Germany
P. Falkai

S-28-002
Functional dysregulations in the language and limbic system as a basis for specific symptoms of schizophrenia
W. Strik, Bern, Switzerland

S-28-003
Dopamine dysfunction and alterations of reward-related learning in schizophrenia
A. Heinz, Berlin, Germany
A. Pankow, A. Beck, F. Schlagenhauf

S-28-004
Dopamine: the final common pathway to psychosis? – New data from the prodome and chronic schizophrenia
O. Howes, London, United Kingdom

O-06  ORAL PRESENTATIONS
08.30 – 10.00 h  Princeton
Genetics and neurobiology
Chairs: D. Rujescu, Munich, Germany
U. Schall, Waratah, Australia

O-06-001
Rare variants in the schizophrenia-associated microdeletion region on 1q21.1
F. B. Basmanav, Bonn, Germany

O-06-002
Gene expression and schizophrenia phenotype in the course of antipsychotic pharmacotherapy
U. Schall, Waratah, Australia
N. Kumarasinghe, P. Rasser, P. Tooney

O-06-003
Gene expression of HERG1, HERG2 and HERG3 isoforms in peripheral blood mononuclear cells of schizophrenia patients
F. Atalar, Istanbul, Turkey

O-06-004
BDNF and S100B as biomarkers in schizophrenia spectrum disorders?
N. van de Kerkhof, Venray, The Netherlands
F. van der Heijden, D. Fekkes, W. Verhoeven

O-06-005
Impaired long-term potentiation and long-term depression in schizophrenia: new insights towards reduced neuroplasticity
A. Hasan, Göttingen, Germany
M. Nitsche, B. Rein, M. Herrmann, R. Aborowa, T. Schneider-Axmann, B. Guse, O. Gruber, P. Falkai, T. Wobrock

O-06-006
Association of candidate genes with neuro-imaging phenotypes: results from the Homburg Multidignosis Study (HMS)
O. Gruber, Göttingen, Germany
P. Falkai
## W-04 WORKSHOPS

**10.30 – 12.00 h**  
**Plenary Room**

**European practice guidelines: a need for harmonisation?**

*Chairs: W. Gaebel, Düsseldorf, Germany  
K. Wahlbeck, Helsinki, Finland*

### W-04-001

**ADAPTE: a systematic approach to cross-cultural and cross-organizational guideline adaptation**

*J. A. Swinkels, Amsterdam, The Netherlands*

### W-04-002

**Recommendations on pharmacological treatment – recent updates**

*W. Gaebel, Düsseldorf, Germany*

### W-04-003

**NICE recommendations on psychological treatments – recent updates**

*E. Kuipers, London, United Kingdom*

### W-04-004

**How much pan-European consensus is necessary?**

*K. Wahlbeck, Helsinki, Finland*

*Discussants:  
A. Fink-Jensen, Copenhagen, Denmark  
A. Gumley, Glasgow, Scotland  
J. Libiger, Hradec Králové, Czech Republic  
A. Meneghelli, Milan, Italy  
R. K. R. Salokangas, Turku, Finland*

## S-29 SYMPOSIA

**10.30 – 12.00 h**  
**Harvard**

**Understanding minds: a conceptual framework in the research and clinical features of schizophrenia**

*Chairs: M. Procacci, Rome, Italy  
R. Popolo, Rome, Italy*

### S-29-001

**Theory of mind in at-risk stages of schizophrenia**

*M. Brüne, Bochum, Germany*

### S-29-002

**Vulnerable self, poor understanding of others’ mind, threat anticipation and cognitive biases as triggers for delusional experience in schizophrenia: a theoretical model**

*G. Salvatore, Rome, Italy  
P. H. Lysaker, R. Popolo, M. Procacci, A. Carcione, G. Dimaggio*

### S-29-003

**Associations of mastery with daily function in schizophrenia**

*P. Lysaker, Indianapolis, USA  
M. Procacci, A. Carcione, G. Salvatore, R. Popolo, G. Dimaggio*

### S-29-004

**Functional neuroimaging of Theory of Mind (ToM) abilities in patients with schizophrenia**

*K. Koelkebeck, Münster, Germany  
A. Pedersen, J. Bauer, M. Brandt, P. Ohrmann*
### S-30 SYMPOSIA

**10.30 – 12.00 h**  
**Stanford**

**Early recognition and early intervention: facts and visions**

*Chairs: J. Klosterkötter, Cologne, Germany  
E. Meisenzahl, Munich, Germany*

**S-30-001**  
**Prediction of psychosis – current state and future directions**  
*S. Ruhrmann, Cologne, Germany  
J. Klosterkötter*

**S-30-002**  
**Prediction of psychosis with neurobiological markers**  
*E. Meisenzahl, Munich, Germany*

**S-30-003**  
**Neurophysiological paradigms in patients at ultra high risk for developing psychosis**  
*D. Nieman, Amsterdam, The Netherlands  
S. Dragt, M. van Tricht, J. Koelman, L. Bour,  
E. Velthorst, D. Linszen, L. de Haan*

**S-30-004**  
**Indicated prevention in people at-risk of psychosis: recent findings**  
*A. Bechdolf, Cologne, Germany*

### S-31 SYMPOSIA

**10.30 – 12.00 h**  
**Princeton**

**Animal models of schizophrenia between genotype, endophenotype, nongenetic second hit and the disease**

*Chairs: R. Wolf, Bochum, Germany  
M. von Wilmsdorff, Düsseldorf, Germany*

**S-31-001**  
**Schizophrenia-related behavioral and hippocampal morphological alterations after prenatal kainic acid lesions**  
*M. von Wilmsdorff, Düsseldorf, Germany  
M.-L. Bouvier, A. Schmitt, W. Gaebel*

**S-31-002**  
**The reeler mouse model of schizophrenia: from behavior to proteomics**  
*A. Schmitt, Göttingen, Germany  
P. Pilz, D. Martins-de-Souza, M. von Wilmsdorff, P. Falkai*

**S-31-003**  
**Region-specific alteration of GABAergic markers in the brain of heterozygous reeler mice**  
*S. Nullmeier, Magdeburg, Germany  
P. Panther, H. Dobrowolny, H. Schwegler, R. Wolf*

**S-31-004**  
**Neurodevelopmental disorder in Srgap3-/-mice leads to lethal hydrocephalus or 'schizophrenia-related' behaviors**  
*R. Weltereit, Mannheim, Germany  
U. Leimer, O. von Bohlen und Halbach, J. Panke,  
S. Hölter, L. Garrett, K. Wittig, M. Schneider,  
C. Schmitt, J. Calzada-Wack, F. Neff, L. Becker,  
C. Prehn, V. Endris, G. Rappold, H. Fuchs, V. Galius-Durner, J. Adamski, T. Klopopack, I. Esposito,  
T. Wieland, W. Wurst, M. Habre de Angelis,  
D. Bartsch*
PL-03 PLENARY LECTURES
12.15 – 13.00 h Plenary Room
Social cognition in schizophrenia
Chair: S. Galderisi, Naples, Italy

PL-03-001 Social cognition and schizophrenia
M. F. Green, Los Angeles, USA

P-08 POSTER SESSIONS
13.30 – 14.30 h Foyer
Outcome
Chair: M. Birchwood, Birmingham, United Kingdom

P-08-001 Clinical and social correlates of “Duration of Untreated Psychosis” (DUP): results from the Catalan Early Psychosis Specific Intervention Programme (EPSIP)
A. Barajas, Barcelona, Spain

P-08-002 Severity of outcome in early psychosis: risk and protective factors in a 7-year retrospective study
S. Ingridolli, Rome, Italy
D. Pucci, S. Ferracuti, G. Ducci

P-08-003 Predictors of short- and long-term clinical outcome in schizophrenic psychosis – the Northern Finland 1966 birth cohort study
P. Juola, Oulu, Finland
J. Miettunen, J. Veijola, M. Isohanni, E. Jaaskelainen

P-08-004 Clinical vs cognitive symptoms as predictors of outcome in psychosis: a longitudinal study
J. Peña, Bilbao, Spain

P-08-005 Early psychosis intervention: a recovery-oriented project in South Tyrol
K. Furlato, Bolzano, Italy
M. Perini, S. Daimo, A. Conca, S. Torresani

P-08-006 Key issues in recovering from first episode psychosis: a factor analysis of the Psychosis Recovery Inventory (PRI)
E. Y. Chen, Hong Kong
W. W. Tam, C. L. Hui, M. M. Lam, S. K. Chan, W. Chang, G. H. Wong

P-08-007 Factors contributing to stigma resistance in patients with schizophrenia
W. Kollmann, Vienna, Austria
M. Amering, B. Schrank, I. Sibitz

P-08-008 The influence of self-stigma on success in work or study among people with schizophrenia
E. Horsselenberg, Assen, The Netherlands
M. Pijnenborg, C. Slooff, J. Arends, A. Aleman

P-08-009 Clinical and social dimensions of disability at schizophrenic spectrum disorders patients with anhedonia: impact on quality of life
N. Orlova, Kiev, Ukraine
M. Shkliar

P-08-010 The ITHACA-Toolkit (German version): validation of an interview manual and toolkit to assess human rights and physical health of residents in psychiatric and social care institutions
H. Zäske, Düsseldorf, Germany
W. Gaebel
P-09 – POSTER SESSIONS

13.30 – 14.30 h  
Foyer

Neuropsychology I: Basic
Chair:  M. Rapp, Berlin, Germany

P-09-001
Age at onset and executive function in schizophrenia
A. Holmén, Lørenskog, Norway
M. Juuhl-Langseth, R. Thormodsen, K. Sundet, B. R. Rund, I. Melle

P-09-002
Cognition and functioning of patients with first psychotic episode and relation with the Brain Derived Neurotrophic Factor
M. Martinez-Cengotitabengoa, Vitoria, Spain
B. Garcia-Lecumberri, S. Alberich, I. Gonzalez-Ortega, S. Ruiz de Azúa, P. Lopez, A. Gonzalez-Pinto

P-09-003
Sustained attention and working memory, but not executive function, deficits follow a familial pattern in schizophrenia
S. Giakoumaki, Rethymno, Greece
P. Roussos, E. G. Pallis, P. Bitsios

P-09-004
Impaired top-down processing in schizophrenia in the perception of a hollow mask revealed with fMRT and event-related-potentials
W. Dillo, Hannover, Germany
D. Dima, H. Emrich

P-09-005
Neural correlates of impaired volition in schizophrenia
J. Bender, Berlin, Germany
B. Reuter, C. Kaufmann, N. Kathmann

P-09-006
Mechanisms of prediction in patients with psychosis
R. Lencer, Münster, Germany
A. Sprenger, P. Trillenberg

P-09-007
Impaired pantomime in schizophrenia – association with frontal lobe function
S. Walther, Bern, Switzerland
T. Vanbellingen, S. Bahlhalter

P-09-008
Negative capability: a poetic-based cognitive resource in early psychosis
M. Lanzaro, Scunthorpe, United Kingdom

P-09-009
Data gathering reasoning bias in patients with at-risk mental states: cognitive and poetic techniques
M. Lanzaro, Scunthorpe, United Kingdom

P-09-010
Electrophysiological markers in bipolarity
A. Boxus, Thuir, France
P. Rayaud, C. Palix

P-09-011
Measuring mismatch negativity (MMN) in the rat – methodological considerations for translational studies of schizophrenia
P. Michie, Callaghan, Australia
T. Nakamura, W. Fulham, U. Schall, J. Todd, T. Budd, D. Hodgson
P-10 POSTER SESSIONS
13.30 – 14.30 h Foyer

Neuropsychology II: Clinical
Chair: M. Green, Darlinghurst, Australia

P-10-001
Differences in the internalizing attribu-
tional style of patients with a first episode psychosis depending on their cognitive and insight impairment
J. Peña, Bilbao, Spain
A. Garcia Guerrero, J. Garcia Ormaza, Y. Ballor-
cca Arnaiz, A. Ugarte Ugarte, K. Haidar, L. Martín
Otaño, E. Bengoetxea Noreña, M. Gutiérrez
Fraile

P-10-002
Neurocognition and social cognition in
early prodromal state of psychosis: pre-
liminary results
M. Skuhareuskaya, Minsk, Belarus
N. Khomenka, O. Skugarevsky

P-10-003
Facial emotion recognition in subjects a
ultra high risk for psychosis: a review
P. A. Martins, São Paulo, Brazil
P. Gonçalves, L. Monteiro, M. Louza

P-10-004
Mental states at risk of psychosis in youth adult: relationship between cognitive symp-
toms and basic symptoms
S. Ingretolli, Rome, Italy
C. Cannizzaro, D. Mallardi, F. Mola, G. Ducci, G. Scifoni

P-10-006
The efficacy of Integrated Psychological Therapy (IPT) for middle-aged schizophrenia patients
D. R. Müller, Bern, Switzerland
S. J. Schmidt, V. Roder

P-10-007
Clinical and cognitive outcomes in schizo-
phrenia/psychosis after cognitive remedia-
tion with REHACOP
N. Ojeda, Bilbao, Spain
J. Peña, E. Bengoetxea, R. Segarra, P. M. Sán-
chez, E. Elizagárate, J. García, J. I. Egiluz,
A. García

P-10-008
Effect of cardiovascular exercise on mental
and physical health in patients with schizo-
phrenia
T. Scheewe, Utrecht, The Netherlands
A. Kroes, T. Takken, F. Backx, R. Kahn, W. Cahn

P-10-009
Enhancing synaptic plasticity and cognition
by aerobic exercise and cognitive training
in chronic schizophrenia: design for a ran-
domised controlled trial
B. Malchow, Göttlingen, Germany
T. Wobrock, P. Falkai

P-10-010
No effect of aerobic exercise on the amyg-
dala and vermis cerebelli in patients with
chronic schizophrenia
B. Malchow, Göttlingen, Germany
M. Schnur, F.-G. B. Pajonk, P. Falkai

P-10-011
In schizophrenia requirements of stereopsis
misguide foveal fixation of the target of att-
tention
H. Korn, Eichstätt, Germany
POSTER SESSIONS

Psychosocial treatment

Chair: E. Kuipers, London, United Kingdom

P-11-001
Processes of therapy in cognitive behavioural therapy for psychosis – a study in progress
M. Wiesjahn, Marburg, Germany
E. Jung, W. Rief, T. M. Lincoln

P-11-002
Predictors for the early therapeutic alliance in cognitive behavioural therapy for psychosis
E. Jung, Marburg, Germany
M. Wiesjahn, T. M. Lincoln

P-11-003
Eagerness to understand illness in adult first-episode psychosis patients
W. Tam, Hong Kong

P-11-004
Psychoeducation in schizophrenia – results of a survey of all psychiatric providers in the Czech Republic in 2009
L. Bankovska Motlova, Prague, Czech Republic
E. Dragomirecka, A. Blabolova, F. Spaniel

P-11-005
The influence of psychoeducative family intervention in schizophrenic patients on perceived quality of life
W. Gassmann, Riedstadt, Germany
O. Christ, H. Berger

P-11-006
The effect of family psychoeducational intervention on family burden and patients’ quality of life in Iranian outpatients with schizophrenia
M. Shaygan, Shiraz, Iran
F. Sharif

P-11-009
Identification of psychosocial necessities associated with aging in schizophrenia
M. L. Vargas, Segovia, Spain
P. Quintanilla, B. Bega, A. Lozano, J. M. Martinez Sanchez, D. Lopez Gomez, R. Martinez de Benito, C. Fernandez Atienza, M. Lorente Williams, A. de la Calle Sanz

P-11-010
A group treatment protocol for comorbid personality disorder
H. Wolters, Assen, The Netherlands
E. Horsellenberg

P-11-011
Psychological group therapy for panic disorder with or without agoraphobia
J. de Santiago, Barcelona, Spain
M. A. Sánchez
### S-32 SYMPOSIA

14.30 – 16.00 h  Plenary Room
Classification of different long term outcomes of psychosis in schizophrenia spectrum – a need for re-conceptualization

**Chairs:** M. Nordentoft, Copenhagen, Denmark  
J. L. Vazquez Barquero, Madrid, Spain

<table>
<thead>
<tr>
<th>Symposium ID</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-32-001</td>
<td>Biological and social predictors of clinical outcome after the first psychotic episode: findings from the AESOP 10-year follow-up study</td>
<td>P. Dazzan, London, United Kingdom</td>
</tr>
</tbody>
</table>
| S-32-002    | Quality of life and recovery in psychotic disorders: ten-years follow-up of the TIPS study | I. Melle, Oslo, Norway  
| S-32-003    | The clinical relevance of the different criteria of “outcome” in psychosis: a critical analysis from the Cantabria First Episode Study | J. L. Vazquez Barquero, Madrid, Spain  
B. Crespo-Facorro, R. Pérez-Iglesias, J. Vázquez-Bourgon |
| S-32-004    | Differences in course of illness and predictors of bad outcome and recovery in the OPUS I cohort after five and ten years | R. G. Secher, Copenhagen, Denmark  
S. Austin, N. Albert, M. Nordentoft |

### S-33 SYMPOSIA

14.30 – 16.00 h  Harvard
Molecular linkage between energy metabolism and oligodendrocyte pathology in schizophrenia

**Chairs:** J. Steiner, Magdeburg, Germany  
A. Schmitt, Göttingen, Germany

<table>
<thead>
<tr>
<th>Symposium ID</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>S-33-001</td>
<td>Neurobiology of feeding and energy expenditure</td>
<td>T. L. Horvath, Magdeburg, Germany</td>
</tr>
</tbody>
</table>
| S-33-002    | Postmortem and PET studies are indicating impaired cerebral glucose metabolism in schizophrenia | J. Steiner, Magdeburg, Germany  
H.-G. Bernstein, B. Bogerts |
| S-33-003    | Histological studies of oligodendrocytes in psychiatric diseases | A. Schmitt, Göttingen, Germany  
| S-33-004    | Impaired biochemical pathways in schizophrenia: a proteomic overview | D. Martins-de-Souza, Cambridge, United Kingdom |
SCIENTIFIC PROGRAMME – Saturday, 1 October 2011

S-34 SYMPOSIA
14.30 – 16.00 h Stanford

Heterogeneity and functional significance of white matter changes in schizophrenia
Chairs: T. Kasparek, Brno, Czech Republic
R. Mandl, Utrecht, The Netherlands

S-34-001
Heterogeneity of diffusion tensor imaging findings in schizophrenia
M. Kyriakopoulos, London, United Kingdom

S-34-002
Methods of white matter tracts integrity investigation
R. Mandl, Utrecht, The Netherlands

S-34-003
Microstructural alterations of the acurate fasciculus are associated with auditory verbal hallucinations in psychotic and in non-psychotic individuals
A. de Weijer, Utrecht, The Netherlands

S-34-004
Multimodal analysis (DTI, fMRI) neurobiological substrates of neurological soft signs in schizophrenia
T. Kasparek, Brno, Czech Republic
J. Rehulová, M. Kerkovský, P. Bednarík

O-07 ORAL PRESENTATIONS
14.30 – 16.00 h Princeton

Neuropsychology and neuroimaging
Chairs: W. Wölwer, Düsseldorf, Germany
S. Kaiser, Zurich, Switzerland

O-07-001
Verbal memory in first episode schizophrenia – a five year follow-up (TIPS study)
H. E. Barder, Oslo, Norway

O-07-002
Specificity and relevance of planning deficits in schizophrenia
S. Kaiser, Zurich, Switzerland
D. Holt, J. Wolf, K. Rodewald, M. Rentrop, J. Funke, M. Weisbrod

O-07-003
Cognitive identity: a dimensional cognition model for schizophrenia
S. Langgraf, Berlin, Germany
I. Amado, M.-O. Krebs, J.-P. Olié, E. van der Meer

O-07-004
Slowed response initiation in schizophrenia: evidence from lateralized movement-related and attention-related brain potentials
D. Möllers, Berlin, Germany
B. Reuter, N. Kathmann

O-07-005
Egocentric spatial navigation in schizophrenia. Differentiated impairment and challenge-dependent activation of mesiotemporal, retrosplenial and parietal regions
J. Siemerkus, Zurich, Switzerland
E. Irle, C. Schmidt-Samoa, M. Mehliitz, J. Baudewig, P. Dechent, G. Weniger

O-07-006
Trust versus paranoia: investigating the neural mechanisms of social reward learning in health and psychosis
P. Gromann, Amsterdam, The Netherlands
S. Shergill, D. Heslenfeld, D. Joyce, A.-K. Fett, L. Krabbendam
PSYCHIATRY CONGRESS BERLIN

Annual Congress of the German Association for Psychiatry and Psychotherapy
23 – 26 November 2011 // ICC Berlin, Germany

Personalised Psychiatry and Psychotherapy

- Special Sessions with
  J. Raymond DePaulo Jr. (Baltimore/USA)
  Arno Villringer (Leipzig, Germany)
  Wulf Rössler (Zurich/Switzerland)
  Niels Birbaumer (Tübingen, Germany)
  Günter Wallraff (Cologne, Germany)
  Manfred Lütz (Cologne, Germany)
  Angaangaq Angakkorsuaq, Shaman of the Eskimo-Kallalit (Greenland)

- More than 30 CME credits possible
- International Track (english)
- Educational Symposia
- Attendance is free to new members 2011
- Congress Kindergarten

Video-Live-Interviews with
Eric Kandel (New York, USA)
Stephen Bergman (Boston, USA)

Further information and the complete congress programme is now available at www.psychiatry-congress-berlin.org
Beyond Diversity Towards Harmony

20th EUROPEAN CONGRESS OF PSYCHIATRY - EPA 2012

Prague, Czech Republic
3-6 March 2012

SUBMIT YOUR ABSTRACT
Deadline: 5 October 2011
ACKNOWLEDGEMENTS

The organisers of the 3rd European Conference on Schizophrenia Research gratefully acknowledge the financial support of the following companies:

Lilly Deutschland GmbH  
Schattauer GmbH  
Astra Zeneca  
Lilly Deutschland  
BioLineRx Ltd.  
Lehmanns Media

FLOORPLAN
INDEX OF CHAIRPERSONS, AUTHORS AND PRESENTERS

N
Navarrete Rueda, F. .................................................. 29
Nenadic, I. .............................................................. 32
Nielsen, M. ............................................................. 17
Niemann, D. ............................................................. 41
Nordentoft, M. ...................................................... 14, 34, 38, 46
Nova Bethania, S. C. ............................................. 17
Nullmeier, S. ............................................................. 41
O
Ojeda, N. ................................................................. 44
Orlova, N. ............................................................... 42
Ortega-Alvaro, A. ................................................... 31
Ortuño, F. ................................................................. 18
P
Papageorgiou, K. ...................................................... 27
Papassotiropoulos, A. ................................................. 29, 32
Parmentier, H. ......................................................... 34
Pelayo Teran, J. M. ................................................... 23
Peña, J. .......................................................... 42, 44
Pendlebury, J. .......................................................... 23
Penttilä, M. ............................................................. 27
Petek Eric, A. ............................................................. 17
Pi, E. ................................................................. 32
Pijnenborg, M. ........................................................... 21
Pletnikov, M. ............................................................ 15
Popolo, R. .............................................................. 37, 40
Pose Cabarcos, A. .................................................... 17
Power, P. ............................................................... 38
Prckaerts, J. ............................................................. 22
Priller, J. ................................................................. 21
Procacci, M. ............................................................. 40
Pujol, N. ................................................................. 18
Q
Quednow, B. .......................................................... 35
Quisenaerts, C. ....................................................... 33
R
Rachow, T. ............................................................. 30
Rahim, T. ................................................................. 17
Rapp, M. .............................................................. 24, 43
Rasmussen, H. ....................................................... 16
Reichenberg, A. ...................................................... 24, 32
Rik, N. ................................................................. 29
Rizos, E. ................................................................. 18
Robert, P. H. .......................................................... 24
Roder, V. ................................................................. 26
Rodgers, S. A. .......................................................... 28
Roesch-Ely, D. ............................................................ 16
Romm, K. L. ............................................................ 27
Rührmann, S. ......................................................... 27, 32, 41
Rujescu, D. ............................................................. 25, 35, 39
S
Sabbe, B. .............................................................. 17, 33
Salokangas, R. K. R. ................................................. 27
Salvatore, G. ............................................................ 40
Sartorius, N. ......................................................... 14, 23, 34
Schall, U. ............................................................... 39
Secheewe, T. .......................................................... 32, 44
Sechennach-Wolf, R. ................................................ 36
Schlagenhauf, F. ...................................................... 24
Schmidt, S. J. ............................................................. 37
Schmitt, A. .............................................................. 39, 41, 46
Schneider, F. ........................................................... 26
Schulze, T. .............................................................. 20, 25
Secher, R. G. ........................................................... 37, 46
Shaygan, M. ............................................................. 45
Sibitz, I. ................................................................. 37
Siemerkus, J. ............................................................ 18, 47
Skuhareuskaia, M. ................................................... 44
Smirnova, L. ............................................................ 29, 30
Spaniel, F. ............................................................... 34
Steiner, J. ............................................................... 46
Steylen, P. .............................................................. 17, 23
Strik, W. ................................................................. 17, 26, 39
Suazo, V. ................................................................. 18
Swinkels, J. A. ........................................................... 40
Szafranski, T. .......................................................... 16
T
Tam, W. ................................................................. 45
Tandon, R. ............................................................. 14, 28
Tani, H. ................................................................. 17
Tomasetti, C. ........................................................... 29
Tschacher, W. .......................................................... 38
Turrina, C. ............................................................. 24
U
Uchida, H. ............................................................. 16
Uehara, T. ............................................................... 31
Urbay, T. ............................................................... 31
Uzun, S. ................................................................. 16
V
van de Kerkhof, N. ................................................... 28, 39
van der Gaag, M. ..................................................... 22, 38
van der Meer, L. ..................................................... 21
van Geert, S. ........................................................... 17, 23
van Haren, N. .......................................................... 34
van Niekerk, M. ....................................................... 36
Vargas, M. L. ........................................................... 45
Vasilev, A. ............................................................... 16
Vázquez Barquero, J. L. ........................................... 46
Venga, E. ................................................................. 30
Verhoeven, W. .......................................................... 28
von Wilmsdorff, M. .................................................. 41
W
Waddington, J. ......................................................... 23
Wagner, M. ............................................................. 20, 35
Wahlbeck, K. ............................................................ 40
Walter, R. ................................................................. 41
Walter, H. ............................................................... 35
Walther, S. ............................................................... 23, 43
Weiner, I. ................................................................. 15
Wiesjahn, M. ............................................................ 45
Wittorf, A. ............................................................... 20
Wobrock, T. ............................................................. 35
Wolf, A. ................................................................. 30
Wolf, R. ................................................................. 41
Wolters, H. ............................................................. 45
Wölwer, W. ............................................................. 27, 47
Wulf, S. ................................................................. 17
Wüstenberg, T. .......................................................... 21
Z
Zäske, H. ................................................................. 42
Zelenko, H. ............................................................. 31
CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 25 years.

We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- inhouse graphic design
- association management

www.cpo-hanser.de
ZypAdhera® – mit der Depotformulierung von Zyprexa® können Sie Ihren Patienten eine dauerhaft gute Perspektive ermöglichen.

- Zuverlässige Redizivprophylaxe von Zyprexa® als Depotformulierung
- Rascher Wirkeintritt nach der 1. Injektion – ohne orale Zusatzgabe
- Hohe Flexibilität (individuelle Dosierung und 2- oder 4-wöchiges Injektionsintervall)

ZypAdhera® – für eine dauerhaft gute Perspektive